Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprises of various intra-articular and hyaluronic acid injections, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise ultrasonic products offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; bone graft substitutes, a portfolio includes various products that facilitate optimal bone fusion. The company's product includes, nexus, an ultrasonic surgical system, an ultrasonic surgical platform; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite, a handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies, which includes minimally invasive fracture treatments and rehabilitation products. Its products include Exogen, an ultrasound bone stimulation system; and Talisman pulse generator and receiver for peripheral nerve stimulation. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Bioventus Inc.

In a report released on July 13, Cameron Halkett from Canaccord Genuity maintained a Buy rating on Bravura Solutions Limited, with a price target o...

Canaccord Genuity Reaffirms Their Buy Rating on Bravura Solutions Limited (BVS)

Macquarie analyst maintained a Hold rating on Bravura Solutions Limited today and set a price target of A$2.34. Bravura Solutions Limited has an an...

Bravura Solutions Limited (BVS) Receives a Hold from Macquarie

Canaccord Genuity analyst Cameron Halkett maintained a Buy rating on Bravura Solutions Limited on July 9 and set a price target of A$2.73. The comp...

Bravura Solutions Limited (BVS) Gets a Buy from Canaccord Genuity

Bravura Solutions Limited ( ($AU:BVS) ) has issued an announcement. Bravura Solutions Limited has notified the market of the issue or conversion of...

Bravura Issues Notice on Conversion of Unquoted Equity Securities

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Atai Beckley N.V. (ATAI), Bioventus (BVS) and Crin...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Atai Beckley N.V. (ATAI), Bioventus (BVS) and Crinetics Pharmaceuticals (CRNX)

Barrington analyst Michael Petusky maintained a Buy rating on Bioventus today and set a price target of $14.00. According to TipRanks, Petusky is a...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BVS	$11.68	-3.19%	545.05K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BVS	$11.68	-3.2%	545.05K
3
4
5
6

BVS

BVS

Get Bioventus Inc. Data in Excel

Get Bioventus Inc. Data in Excel